Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25 – 26, 2023. The company will engage in a fireside chat on April 26 at 11 AM ET, which can be accessed via a webcast. The corporate presentation will be archived for 90 days on their Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics aimed at treating various human diseases. Central to their research is the relationship between angiogenesis, the immune system, and tumor growth. Their innovative pipeline targets critical biological pathways to enhance anti-tumor responses. For further details, visit www.compasstherapeutics.com.
- None.
- None.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.
Fireside Chat details:
Date: Wednesday, April 26
Time: 11 AM ET
Webcast: https://wsw.com/webcast/stifel78/cmpx/2115088
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
What event will Compass Therapeutics participate in on April 25-26, 2023?
When is the fireside chat for Compass Therapeutics at the oncology event?
How can I access the fireside chat for Compass Therapeutics?
Will the presentation from Compass Therapeutics be available after the event?
What is the focus of Compass Therapeutics' research?
